NEW YORK, April 9, 2021 /PRNewswire/ — The cancer treatment market is one of the biggest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8 million people were diagnosed with cancer in the United States in 2020. Overall, lung and bronchus cancer is the second most common cancer diagnosis with an estimated 228,820 new cases. Prostate cancer is the leading cancer diagnosis among men and the third most common diagnosis overall with 191,930 expected cases. However, the increase in competition and continuous technological advancements has led to improvements in the product portfolios of biotech firms in the field. Therefore, product approvals and product development are one of the key developmental strategies adopted by market players in the global cancer therapeutics market. And, according to a report by Mordor Intelligence, the breast cancer segment is projected to account for the largest market size over the forecast period of 2020–2025. As per estimates provided by the Breast Cancer Organization in 2018, it is estimated that over 2,66,120 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, along with 63,960 new cases of non-invasive (in situ) breast cancer. Todos Medical Ltd. (OTC: TOMDF), Agenus Inc. (NASDAQ: AGEN), Leap Therapeutics, Inc. (NASDAQ: LPTX), Trillium Therapeutics Inc. (NASDAQ: TRIL), Verastem, Inc. (NASDAQ: VSTM)
New technologies and innovation will play a major…
